Melbourne Australia;
5 November 2019 – Key United States Patent covering OBM-1701 Granted
Melbourne, Australia; 31 August 2018 – Batch of OBM-1701 was Successfully Manufactured with High Purity
August 31, 2018Melbourne, Australia; 18 February 2020 – OBM Signs Non-Binding Heads of Agreement with Lanka Graphite Limited
February 18, 2020Oculus Biomed Limited (“OBM”) is pleased to announce the grant of the USA Patent which covers its OBM-1701. The term of the Chinese patent extend its patent protection to April 2036 and covers OBM-1701 and its analogues and their use to treat disorders involving neovascularisation, including eye diseases such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). Corresponding patent applications have already been granted in 4 other countries, including, Japan, Australia, New Zealand, and Taiwan, and are pending in 12 other countries and territories.
